Document |
Document Title |
WO/2024/102369A1 |
The present disclosure provides antibodies that bind to the catalytic domain of Factor XI (FXI) and methods of using the same. According to certain embodiments, the antibodies are antagonist antibodies that inhibit blood clot formation v...
|
WO/2024/102306A1 |
Prodrugs and methods for preventing and/or treating one or more symptoms of sickle cell diseases (SCD) or respiratory hypoxia by administering at least one of the compounds are provided. The compounds are prodrugs that are chemically mod...
|
WO/2024/100663A1 |
Pharmaceutical compositions comprising anti-CEACAMl mAbs, and their use in inhibition of NET-mediated activities, and in prevention and treatment of pathologies associated with these activities are provided and exemplified with the mAb C...
|
WO/2024/100213A1 |
The present invention relates to iron nanoclusters having the following features: - they are covered on their surface by a mixed layer comprising histidine (His), acetate ions (Ac) and ascorbate ions (Asc); - they are spherically shaped;...
|
WO/2024/098383A1 |
Disclosed are a protein mutant with a sequence having more than 80% identity to SEQ ID NO. 1, a gRNA used in combination with the protein mutant, a gene editing system, an expression vector, a modified cell, a pharmaceutical composition,...
|
WO/2024/099865A1 |
The present invention refers to a cell suspension of autologous adult bone marrow-derived mononuclear cells for use in the treatment or amelioration of a subject suffering or having suffered from an ischemic or a hemorrhagic stroke and m...
|
WO/2024/101209A1 |
The purpose of the present invention is to provide: a composition for preventing the deterioration in kidney functions or improving kidney functions; and a method for preventing the deterioration in kidney functions or improving kidney f...
|
WO/2024/098238A1 |
β-Hemoglobinopathies are hereditary diseases that originate from mutations in the hemoglobin beta (HBB) gene. The general inventive concepts are based on the discovery that hemoglobinopathies can be treated by administration of a dual v...
|
WO/2024/099346A1 |
The present invention provides use of a compound as represented by formula I or a pharmaceutically acceptable salt or ester thereof in the preparation of a drug for treating ASC-caspase-1 pathway-based inflammasome activation-mediated di...
|
WO/2024/101159A1 |
A pharmaceutical composition comprising nano-fibers and/or nano-flakes of a material represented by formula: MQaOb (in the formula, M represents at least one element selected from the group consisting of group 3, 4, 5, 6 and 7 elements, ...
|
WO/2024/076993A3 |
Described herein are multi-specific antigen binding proteins that bind human fibrin or fibrinogen γC domain and vascular endothelial growth factor, and methods of use thereof. In certain aspects, described herein are pharmaceutical comp...
|
WO/2024/100067A1 |
Described herein is a dairy product, or a replica thereof, supplemented with a hemeprotein, and a method for preparing such a dairy product, or a replica thereof.
|
WO/2024/102304A1 |
Compounds and methods for preventing and/or treating one or more symptoms of sickle cell diseases (SCD) by administering at least one of the compounds are provided. The compounds are chemically modified to increase bioavailability and ac...
|
WO/2024/099320A1 |
A hybrid protein containing a CFH functional unit and a DAF functional unit, and a mutant thereof, an encoding nucleic acid thereof, and a method and the use thereof for treating diseases or conditions related to a complement system; and...
|
WO/2024/097846A1 |
Provided are pharmaceutical formulations comprising 4-((2-hydroxy-3-methoxybenzyl)amino)-benzenesulfonamide 12-LOX inhibitors with improved solubility for oral administration. Also provides are pharmaceutical formulations comprising sele...
|
WO/2024/095006A1 |
The present invention relates to a therapeutic agent comprising an autoregulation element, preferably wherein the therapeutic agent is an antigen binding protein. Methods of treatment comprising use of said agent are also disclosed.
|
WO/2024/097829A1 |
Described herein are compositions for inhibiting a protease or coagulation target comprising a nucleic acid aptamer covalently linked to a small molecule inhibitor and methods for using the same to inhibit coagulation. Also provided are ...
|
WO/2024/093915A1 |
Provided are a protein comprising an amino acid sequence capable of binding to a substrate GPRP peptide fragment, a fibrinogen like protein 1 (FGL1) comprising the amino acid sequence, and a fibrinogen domain (FD) thereof, and an individ...
|
WO/2024/097571A1 |
Disclosed are compositions and methods for using heme and at least one PAMP and/or DAMP molecule for activating NLRP12 and/or NLRC5 and inflammatory cell death. Also provided is a screening assay for identifying NLRP12 and/or NLRC5 inhib...
|
WO/2024/095012A1 |
The invention relates to a compound of formula (Ia) and related aspects.
|
WO/2024/097163A1 |
Methods of treating paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, or idiopathic immune complex-mediated glomerulonephritis using MASP-3 serine protease inhibitors are provided. In some embodiments, the MASP-3 serine p...
|
WO/2024/095053A1 |
The present invention relates to a novel non-oral formulation of factor Xa inhibitors comprising factor Xa inhibitor and pharmaceutically acceptable excipients selected from vehicles, surface active agents, co-solvents and stabilizers. T...
|
WO/2024/097436A1 |
Compounds for modulating the activity and/or the expression of 5-aminolevulinic acid synthase (ALAS) affecting biological functions. In part, novel compounds and pharmaceutically acceptable salts and in part, methods for preparing the no...
|
WO/2024/097413A1 |
The present invention provides methods of treating anemia in a patient in need thereof, comprising administering to the patient in need thereof an effective amount of formoterol or a pharmaceutically acceptable salt thereof (e.g., formot...
|
WO/2024/095213A1 |
The present disclosure provides nucleic acids, compositions and vectors containing and their use for effecting gene editing and/or gene expression alteration on sickle cell disease (SCD)-associated genes, e.g., in vivo. The present discl...
|
WO/2024/097932A1 |
Disclosed herein are compounds and methods for the prevention and/or treatment of hemoglobinopathies. Also provided herein are such compounds for use in such methods. Also disclosed herein are pharmaceutical compositions comprising such ...
|
WO/2024/097667A1 |
Methods for treating immune thrombocytopenia comprising administering at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-
d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxeta
n-3-yl)pip...
|
WO/2024/087673A1 |
An antiplatelet drug, comprising a platelet inhibitory molecule, a linker, and a capture group. The capture group is a functional group of click chemistry reaction. The antiplatelet drug has good antiplatelet activity, and can be used in...
|
WO/2024/090329A1 |
The present inventors have found that a pyridoxal synthetic enzyme Pyridoxamine-5'-phosphate oxidase (PNPO) acts as an oxygen sensing mechanism for a novel pathway that is independent from an HIF pathway in chronic hypoxia. A pharmaceuti...
|
WO/2024/088302A1 |
The present disclosure relates to a use of Herombopag or a pharmaceutically acceptable salt thereof in treatment of tumor chemotherapy-induced thrombocytopenia. Specifically, the present disclosure relates to a disease treatment method, ...
|
WO/2024/087860A1 |
The present invention relates to a method for obtaining high-purity and high-stability recombinant human albumin by adding medium- and long-chain fatty acid ligands and removing a protein having charge heterogeneity by means of anion or/...
|
WO/2024/092232A1 |
The present disclosure provides a co-formulation that includes an antibody that binds specifically to C5 and a C5 iRNA which is a glycoconjugate that includes a ligand having terminal N-Acetylgalactosamine (GalNAc) residues and/or N-acet...
|
WO/2024/092210A1 |
Provided herein are methods to treat fibrosis and/or inhibit angiogenesis.
|
WO/2024/084214A1 |
The invention relates to Von Willebrand Factor (VWF) antibodies, and particularly, although not exclusively, to antibodies which target the C1-C6 domain of VWF. The invention extends to compositions comprising the antibodies, including p...
|
WO/2024/085149A1 |
The present invention addresses the problem of providing a capsule particle manufacturing method. Provided is a method for manufacturing capsule particles by using a Taylor reactor.
|
WO/2024/083980A1 |
The invention relates to novel compounds of the general formula (I-A) as defined in the application and pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, ...
|
WO/2024/084217A1 |
The present invention provides compounds of formula (I): Formula (I) compositions comprising such compounds; the use of such compounds in medicine; and methods of treating patients with such compounds; wherein R1, B1, B2, B3, B4, B5, and...
|
WO/2024/085325A1 |
The present invention relates to a composition for alleviating, preventing, or treating diseases related to peritoneal fibrosis, comprising tiplaxtinin. The tiplaxtinin of the present invention has an excellent peritoneal EMT inhibitory ...
|
WO/2024/086835A1 |
The present disclosure relates to methods for treating blood transfusion-dependent hematological malignancy patients with oxygen reduced blood.
|
WO/2024/085725A1 |
The present invention pertains to a novel compound derivative and a pharmacological use thereof and specifically to a novel 1,1-dioxo-1,2-benzisothiazole derivative or novel 3-citryl-1H-pyrazole derivatives possessing antiplatelet activi...
|
WO/2024/084501A1 |
The present disclosure relates to crystalline forms of mitapivat, amorphous mitapivat mono sulfate, crystalline forms of mitapivat mono sulfate, and crystalline forms of mitapivat hemi sulfate. The present disclosure also relates to proc...
|
WO/2024/080373A1 |
This reagent for measuring activated partial thromboplastin time contains a polymer having 2-methacryloyloxyethyl phosphorylcholine as a structural unit. This blood coagulation time regulator for a lupus anticoagulant-positive blood spec...
|
WO/2024/080371A1 |
This blood coagulation time shortening agent for a blood specimen deficient in coagulation factor XII for activated partial thromboplastin time measurement uses, as an active ingredient, a polymer having 2-methacryloyloxyethyl phosphoryl...
|
WO/2024/080736A1 |
The present invention provides a feature related to a cored tablet combination preparation comprising clopidogrel or a pharmaceutically acceptable salt thereof and ilaprazole as active ingredients. The cored tablet combination preparatio...
|
WO/2024/079664A1 |
The disclosure provides compositions including a human milk oligosaccharide (HMO), as well as methods of using the same for reducing inflammation of the skin, treating or preventing psoriasis, acne, rosacea, eczema, erythema, UV radiatio...
|
WO/2024/077335A1 |
This invention relates to Factor IX variant polypeptides for administration to soft tissues.
|
WO/2024/077488A1 |
Use of a polygonum capitatum granular preparation in the preparation of drugs for clearing heat and promoting diuresis, inducing diuresis for treating stranguria, treating urinary tract infection or stones, treating pyelonephritis, detox...
|
WO/2024/077856A1 |
Provided in the present invention is the use of a TBX family transcription factor as a target in the preparation of a drug for treating ophthalmic diseases. In the present invention, the TBX family transcription factor is used as a targe...
|
WO/2024/076550A1 |
Disclosed is a method of using Netrin-1 (NTN1) driven rejuvenation of an aged hematopoietic system based on its shown dependency of reestablishing integrity of aged bone marrow niche and reactivating DNA damage response (DDR). NTN1 is sh...
|
WO/2024/077140A1 |
In the various aspects and embodiments, the present disclosure provides cell populations or cell "banks" thereof (e.g., cell collections) to provide immune compatible, allogeneic cell therapies covering global, ethnic, and disease-specif...
|